Since its establishment in 1717, ONO has devoted itself solely to the pharmaceutical industry under the corporate philosophy "Dedicated to the Fight against Disease and Pain." We aim to contribute to society by pharmaceutical products that truly benefit patients. To this end, we are tackling diseases that remain unconquered as yet and addressing areas that are high in healthcare needs where patient satisfaction with current treatment is low.
In FY2020, the novel coronavirus infection spread throughout the world, and we have become a business activity in an environment that we had never experienced before. In order to fulfill our mission as a pharmaceutical company even in this situation, we have taken measures to prevent infection and reduce the burden on medical sites, while working to ensure a stable supply of pharmaceuticals. As a pharmaceutical company, we are also aware of the importance of improving access to healthcare, and are promoting research and development of pharmaceuticals for rare diseases, intractable diseases, and pediatric patients, for which medical needs have not yet been fulfilled.
At the same time, we believe that it is important to contribute to solving social issues and the realization of a sustainable society while listening to the voices of various stakeholders. Under this belief, in addition to endeavoring to create innovative drugs, we continually strengthen our efforts with respect to the environment, society, and governance (ESG).
To achieve the Sustainable Development Goals (SDGs) that have been adopted by the United Nations, we have been identifying our important CSR issues (materiality) for sustainability management since FY2018. In our actual activities, we continually clarify the vision, set concrete targets and Key Performance Indicators (KPI) for each fiscal year, collect and analyze information to identify issues, and promote activities to achieve the SDGs in cooperation with internal and external organizations.
The issue of global warming, including extreme weather events, is becoming increasingly serious in recent years. This has had a major impact on human health, and addressing climate change is one of the critical challenges facing the international community. We believe that while being fully aware of corporate social responsibility for the environment, we should protect the environment in all aspects of our business to play our part in the realization of an abundant global environment. Based on this belief, in June 2019 we formulated the medium- and long-term environmental vision "ECO VISION 2050," pledging to become a leading company in the area of environmental challenges in the pharmaceutical industry by 2050. To achieve "ECO VISION 2050," we determined three priority items, "Realization of a decarbonized society," "Realization of a water recycling society," and "Realization of a resource recycling society," and set specific medium- and long-term reduction goals for greenhouse gas emissions, water use, and waste amounts. We work vigorously to achieve the set goals. In October 2019, we expressed our support for the recommendations of the Task Force on Climate-related Financial Disclosures (TCFD), and have since worked to appropriately disclose information based on the TCFD recommendations. In June 2020, we participated in "RE100" and set the goal of procuring 100% renewable energy for electricity used in our business activities by 2050. Participating in "RE100" is an important step toward achieving the goal of "ECO VISION 2050," and we will further strengthen our efforts to procure and expand the use of renewable energy.
Under the corporate philosophy "Dedicated to the Fight against Disease and Pain," we will continue being passionate challengers. We sincerely ask for your continued support.